India on Sunday reported 12,899 new Covid-19 cases and 15 deaths due to the respiratory infection, according to Union Health Ministry data. Yesterday, the Covid-19 cases crossed the 13,000-mark for the first time after more than three months as 13,216 fresh infections were reported in the last 24 hours.
BA.2 and its sub-lineages account for over 85%of the Covid cases in India, with BA.2.38 being found in around 33% of the samples.
BA.4 and BA.5 are found in less than 10% samples.
Under the nationwide vaccination program, India’s Covid-19 vaccination coverage has exceeded 196 crore (196,13,24,182).
So far, more than 3.57 crore (3,57,14,238) adolescents have been administered the first dose of the Covid-19 vaccine. Overall, 101.30 crore people have taken their first shot of the coronavirus vaccine while 90.68 crore people have been fully vaccinated, according to the Centre’s data.
More than 193.53 vaccine doses have been provided to States/UTs so far, out of which, over 12.89 crores (12,89,73,380) balance and unutilized vaccine doses are still available with them.
Separately, Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech said that the clinical phase III trials of the Covid-19 nasal vaccine have been completed and the company will submit its data to the Drugs Controller General of India (DCGI) next month.
“We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay, then we will get permission to launch and it will be the world’s first clinically proven nasal COVID-19 vaccine,” Bharat Biotech chairman said.